Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The full electric cars and the hybrid plug-in’s are in my opinion superb values on the used market, Especially around San Francisco and the Silicon Valley where many electric and partially electric cars went out on leases and have come back after three years at very attractive prices for value shoppers. That’s what led us to look for an i3. We found a 2015 with range extender, well-equipped and in perfect condition after 24,000 miles, for $16,000 (original MSRP 42,000 +tax). That’s about $4000 less then in other areas outside the bay area. The i3 has the unique advantage of not being limited by its battery capacity if it is equipped with the range extender.
I already own a hybrid plug-in and we have a level 2 charging station Installed in our garage, along with a large solar panel system in sunny Central California. If/when any of my biotechs pay off I’ll be able to afford food too.
I think it’s only concentrated accounts that are being targeted and not because of AMRN specifically. Concentrated accounts don’t have enough other positions to cover the liability in the event of a catastrophic price crash.
OT. OT. BMW I3 - anybody have one? My daughter wants to buy one and we’re going to go for a test drive
Remember the name. Datek was my former brokerage before Ameritrade bought them.
What is a 2% margin account? I am at Ameritrade and have been since they took over another company whose names started with D and I can’t remember the rest. I occasionally use a small amount of margin and haven’t had a margin call in many years. I’m also holding half a dozen complex positions (shares and multiple option positions in some issues). I’m pretty sure the last time I did get a margin call I was heavily concentrated. I’m not at all surprised that concentrated accounts are getting margin pulled, but I would also expect that larger accounts that could produce a balance sheet showing sufficient other assets would be exempt from margin calls even if concentrated, unless they took a hit that left them extremely overleveraged.
I don't think any conclusions about pure EPA 4g/d can be drawn from his remarks since they are all about low dose in fish oil, having pi**ed on the dose response factor. His "time to move on to other therapies" reeks of agenda.
That thoroughly quashes any suggestion that AF is now positive on Amsrin and Vascepa. He’s doing his usual pool boy song and dance bash routine.
You can’t look at only the ask. You have to look at the bid as well, and the size of both. To make it more confusing sometimes option sellers put up false flags, like a bid/ask of 0/$4.50. To know what the right price is to buy or sell in that case you need to use an option calculator, and even then the market maker may not fill your order or may fill at a better price.
Most people should not dabble with options unless they are willing to study how the option market works and what option strategies to use in various circumstances. The majority of long options expire worthless and the buyer gets nothing for his investment (but it may have been justified as a hedge). There is a learning curve and losses to be incurred along the way as you get familiar with options..
I think he was referring to the fact that the option prices changed to a much greater extent than the share price. This is due to change in volatility. When uncertainty Is high the implied volatility skyrockets. The price of a call with a strike price which is above the current share price is all premium (Zero intrinsic value). The premium is mostly volatility premium plus a little bit of time premium. When the uncertainty is removed the volatility will collapse and prices will collapse to intrinsic plus time premium plus a much smaller volatility premium.
During trading hours you can get a close idea of the market value of your options by looking at the bid and ask. As long as there is any size behind them then the ‘mark‘ or current value is the approximate midpoint. To buy an option you have to pay a penny or two or sometimes a nickel more than the midpoint, and to sell an option you can ask a penny or two or sometimes a nickel less than the midpoint.
Outside of trading hours the bid and the ask are not accurate and therefore the mark is not accurate.
Getting a crown fitted, is that all? How about a root canal without anesthetic? I did that twice, granted I have a lot of nerve damage.
I was in Elan as wellt by the way, and actually managed to get out with a profit.
His opinion might be weighted by a research stipend from an entity that stands to gain if Amarin loses, a conflict of interest perish the thought.
Look at the current standard of care for the indications Vascepa addresses or might address. Which procedures and drugs would be threatened if Vascepa becomes the standard of care?
My regular order from the company was shipped and delivered on schedule a few days ago. 3 bottles.
It doesn’t come off as a conversation. It looks like a confrontation. I’m through with this topic.
Why does that matter? Whether he’s in or out he brought up a great point!
Needless to say, I’m not chas but I have a reply to your question.
I thought the question of stopping/not stopping for overwhelming efficacy at the second IA had been put to bed, but you have raised it again. I believe the company put such a strict requirement of robust SE’s on the DMC before they could recommend stopping that no conclusion could be drawn about the PE when they did not recommend stopping. I believe the fallacy that not stopping indicated a less than stellar PE RRR is a fallacy the shorts embraced.
The effective date of that short interest report was August 10 not August 15 (August 15 was settlement date for trades of August 10). I expect the short interest is higher now and I don’t expect any covering prior to topline announcement. I don’t think there’s any change in the short fhesis and the big shorts would see no reason to cover.
I wonder if the market and the clinicians are so entrenched in their ignorance of this moa that topline results even if spectacular will be met with skepticism and even rejection and it will take detailed presentation at a scientific conference and publication in medical journals to turn the tide. After all the negative articles on 0-3 uselessness and after the trial failures of low-dose O-3’s will the response to a successful outcome from Reduc-it be disbelief?
I use speech to text on my iPhone all the time, and oftentimes even though the typed text is what I said, in the second it takes me to tap “post” or “send” spellcheck changes it to something ridiculous.
In my experience, the FDA is not concerned with improving healthcare but rather with protecting their fiefdoms including the right of first night with any biotech virgin, and of course padding their own retirement accounts.
A poker player can misdirect, but an officer of a publicly held company will go to jail for that.
Imagining Kiwi up to his ears in sheetrock evokes images of that fine old wine, Amontillado, a cask of which is to die for.
I too said late September, not for any scientific reason but simply because listening to the guidance there was no reason to expect a release earlier than late September rather than anytime in August.
I do agree totally but the timing of a late September release is much better considering a possible November presentation.
There is a problem with buying puts or calls when volatility is at extremely high levels as it is currently with AMRN. When the results are announced volatility will collapse, creating much lower prices for options before the share price changes even one penny. In fact, the price will have to move up or down a lot just to overcome the loss of the volatility premium paid when the options were purchased. I recall one time selling puts on a particular biotech at five dollars and change. The announcement went against me and the price of the stock dropped a few dollars, but I still made a profit covering my short ports for less than I had sold them for because the volatility dropped so far.
"another decimal on the market cap"
That could cause inflammatory bowel syndrome for the shorts. In that case Vascepa could be the cause and the cure.
If you are confident that R-I will produce at least 15% RRR, and want to make a very high fast return on your money (short term cap gains of course), the market is pricing Sep puts for R-I failure. You can sell Sep $4 puts for about $1.90, which means you need margin or cash reserve of $2.10 to make this play. If you can't imagine AMRN below $4 at Sep expiration, then you will be looking at making $1.90 profit for your $2.10 risk. I have done that as a side bet without selling my core position.
I am a small-time trader, not an investment counselor, so just passing along what I see.
I don’t have a scientific basis for saying seven months, but in 20 years of investing in Biotech I’ve learned that everything always takes longer than I expect. For this reason I keep my expectations in check and look for the announcement later than most people here.
If you buy calls and later exercise them, the cost basis for the shares is the sum of the exercise price and the option cost, including commissions and fees. The basis for long/short term concerns is the date the calls are purchased, not the date of exercise. Furthermore, since the cost of the calls is rolled into the cost basis of the shares, there is no tax question until the shares are sold.
Although I rarely buy calls I frequently sell puts at a strike price which I think will not be attained. I expect to be "put" the shares at the strike price, but my cost basis is the cost of the shares sold to me at the relatively high strike price and the premium received when I sold the puts, generally a good discount from the price of buying shares outright instead of selling puts. For example, if I had sold September $8 puts today at around $5.50, and if the share price is not higher than $8 at September expiration then I would be buying shares at that time for $2.50 ($8 less $5.50 and I will not declare a gain or loss on the puts since that premium is rolled into the cost of the shares). If the share price at expiration is higher than the strike price then the premium received is my profit for the trade closed at expiration.
I highly doubt it. I expect top-line near the end of September, because 7 months from start of final visits is reasonable, and because they never said midsummer, but rather said before the end of Q3. I expect stellar results, but in three months.
Kiwi, let me join in with a hearty me too (belated post because I was out of town and just now catching up on the board).
As I understand it, that's part of the FDA debacle. EPA in the rTG form is a processed chemical and not a foodstuff. Therefore it is defacto in violation of the FDA's definition of a DS. It does not fall within the scope of Amarin's ITC complaint about a mislabeled drug (EE) being sold as a DS.
Kiwi, your continued deliberate misrepresentations are offensive. You can't possibly be ignorant of the fact that commercial omega-3's that are fish oil are not the same as high-purity EPA with no DHA and no contaminants. Amarin claims proprietary rights to highly-purified esterified EPA, an FDA approved drug, and not to fish oil. Step in my proprietary space and I will sue you for infringement and seek an injunction.
You have beaten your dead horse until it was reduced to mash, and it still will not get up and carry you. There is NO difference in the guidance, but there does seem to be a difference between your reading comprehension and everyone else's.
Hey, AF had real world experience to support his political science degree. He was towel boy at the Y.
“, I usually read the local paper during commercials when watching TV at night. ”
Dead giveaway! You are a (fellow) geezer.
Geezer: anyone who grew up before the Internet.
Nobody has to prove anything to you. You're the one with the burden of proof. We haven't seen your facts, just your unfounded theory.
Dear boy,
You have ignored to this point a quite reasonable request for your creds. Where did you get your advanced degrees and what professional experience would qualify you to get on a soap box here and preach your theory. Until you can back your story up with more than a video from whatshisname, you are just another quackjob.
It looks to me like the company is executing a plan for maximum exposure and attention prior to declaring final onset. I wonder if there are further surprises in store for us to hold interest over the coming several months until final results.
Amarin Corporation plc
Amarin Sponsors Multiple Scientific Presentations Scheduled for 2018 American College of Cardiology Annual Scientific Session & Expo
Presentations to Include Additional Real-World Data, Clinical and Cost Analyses of Patient Outcomes From Managed Care Databases
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, is supporting the presentation of four accepted scientific presentations at the American College of Cardiology's 67th Annual Scientific Session and Expo in Orlando, March 10-12, 2018. These presentations, and the underlying data and findings to be presented, were prepared in collaboration with leading health organizations and physicians.
"Amarin is pleased to be working in partnership with leading academic institutions and healthcare providers to research and identify these new and important findings," said Craig B. Granowitz, M.D., Ph.D., senior vice president and chief medical officer of Amarin. "Analyses of cost and disease progression of patients with high triglycerides and other health states are important as tens of millions of adults have cardiovascular disease."
Data to be presented includes:
Poster Presentations
Triglycerides ≥150 mg/dL Associated With Greater Risk of Cardiovascular Events, Costs and Resource Utilization in High-Risk Statin-Treated Patients With Controlled Low-Density Lipoprotein Cholesterol: A Real-World Analysis. Peter P. Toth, Craig Granowitz, Michael Hull, Djibril Liassou, Amy Anderson, Sephy Philip
Long-Term Renal Function Worsens in High Cardiovascular Risk Patients With High Triglycerides and Well-Controlled Low-Density Lipoprotein Cholesterol in a Real-World Analysis. Peter P. Toth, Craig Granowitz, Michael Hull, Djibril Liassou, Amy Anderson, Sephy Philip
Increased Medical Care Costs in Patients with Statin-Controlled Low-Density Lipoprotein Cholesterol and Residual Hypertriglyceridemia. Gregory A. Nichols, Sephy Philip, Craig Granowitz, Kristi Reynolds, Sergio Fazio, Kaiser Permanente Center for Health Research, Portland, OR, USA
Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) Reduces Potentially Atherogenic Lipid, Lipoprotein, Apolipoprotein, and Inflammatory Parameters in High-Risk, Statin-Treated Patients With Persistent Elevated Triglycerides and High-Sensitivity C-reactive Protein: A Post hoc Subanalysis of the ANCHOR Study. Michael Miller, Christie M. Ballantyne, Harold E. Bays, Craig Granowitz, Ralph T. Doyle, Jr, Rebecca A. Juliano, Sephy Philip
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl), Amarin's first FDA-approved product, is a highly-pure, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
About REDUCE-IT
Amarin's clinical development program for Vascepa includes a trial known as the REDUCE-IT cardiovascular outcomes study, an 8,175-patient study commenced in 2011. REDUCE-IT is the first multinational cardiovascular outcomes study evaluating the effect of prescription pure EPA therapy, or any triglyceride lowering therapy, as an add-on to statins in patients with high cardiovascular risk who, despite stable statin therapy, have elevated triglyceride levels (150-499 mg/dL). A large portion of the male and female patients enrolled in this outcomes study are anticipated to also be diagnosed with type 2 diabetes. As reported previously, Amarin expects to announce top-line results of this important study before the end of Q3 2018. The REDUCE-IT trial is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.
Additional information on clinical studies of Vascepa can be found at www.clinicaltrials.gov.
About VASCEPA® (icosapent ethyl) Capsules
Vascepa® (icosapent ethyl) capsules are a single-molecule prescription product consisting of the omega-3 acid commonly known as EPA in ethyl-ester form. Vascepa is not fish oil, but is derived from fish through a stringent and complex FDA-regulated manufacturing process designed to effectively eliminate impurities and isolate and protect the single molecule active ingredient. Vascepa, known in scientific literature as AMR101, has been designated a new chemical entity by the FDA. Amarin has been issued multiple patents internationally based on the unique clinical profile of Vascepa, including the drug's ability to lower triglyceride levels in relevant patient populations without raising LDL-cholesterol levels.
FDA-Approved Indication and Usage
Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.
The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.
Important Safety Information for Vascepa
Vascepa is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of its components.
Use with caution in patients with known hypersensitivity to fish and/or shellfish.
The most common reported adverse reaction (incidence > 2% and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo). There was no reported adverse reaction > 3% and greater than placebo.
Patients receiving treatment with Vascepa and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically.
In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy.
Patients should be advised to swallow Vascepa capsules whole; not to break open, crush, dissolve, or chew Vascepa.
Adverse events and product complaints may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.
FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM.
Vascepa has been approved for use by the United States Food and Drug Administration (FDA) as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Nothing in this press release should be construed as promoting the use of Vascepa in any indication that has not been approved by the FDA.
Forward-Looking Statements
This press release contains forward-looking statements, including statements about the future promotion and commercialization plans for Vascepa; expectations regarding future Vascepa sales and resulting revenue and company expenses for 2018 and inclusive quarterly periods; expectations related to multiple elements of Amarin's 2018 financial outlook such as anticipated expenses, cash balances and financing needs under various scenarios; expectations for continued event rates, timing of last patient visits, results and related announcement timing associated with Amarin's REDUCE-IT cardiovascular outcomes study; expectations related to the successful completion of REDUCE-IT; and statements regarding the potential efficacy, safety and therapeutic benefits of Vascepa, regulatory reviews and approvals of Vascepa internationally and related commercial potential. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. In particular, as disclosed in its previous filings with the U.S. Securities and Exchange Commission, Amarin's ability to effectively commercialize Vascepa will depend in part on efforts of third parties, its ability to create market demand for Vascepa through education, marketing and sales activities, to achieve market acceptance of Vascepa in new and current uses, to receive adequate levels of reimbursement from third-party payers, to develop and maintain a consistent source of commercial supply at a competitive price, to continue to effectively finance its business, to comply with legal and regulatory requirements in connection with the sale and promotion of Vascepa and to maintain patent protection for Vascepa. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally with research and development, clinical trials and related regulatory approvals; the risk that related cost may increase beyond expectations; the risk that Vascepa may not show clinically meaningful effects in REDUCE-IT or support regulatory approvals for intended uses; the risk that patents may not be upheld in patent litigation and applications may not result in issued patents sufficient to protect the Vascepa franchise. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent annual report on Form 10-K. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Availability of Other Information About Amarin
Investors and others should note that Amarin communicates with its investors and the public using the company website (http://www.amarincorp.com/), the investor relations website (http://investor.amarincorp.com/), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin's investor relations website and may include social media channels. The contents of Amarin's website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor Relations:
Elisabeth Schwartz
Investor Relations and Corporate Communications
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
investor.relations@amarincorp.com
Lee M. Stern
Trout Group
In U.S.: +1 (646) 378-2992
lstern@troutgroup.com
Media Inquiries:
Kristie Kuhl
Finn Partners
In U.S.: +1 (212) 583-2791
Kristie.kuhl@finnpartners.com
Primary Logo
Source: Amarin Corporation plc
You are subscribed to Amarin Corporation plc Investor Relations' e-mail alerts as xxxxxxxxxxxxxxxxxxxxxxxx.
To update your e-mail and alert preferences, please click here.
To unsubscribe, please click here.
Amarin Corporation plc
2 Pembroke House, Upper Pembroke Street 28-32, Dublin 2, Ireland
Service provided by Nasdaq
No argument there, plus once an agency has served up a "stop that" wrt selling esterified EPA as DS Amarin can go after the infringers to collect the penalty for their past misdeeds. Of course Amarin doesn't need the agency to act first but that makes the infringement lawsuit more of a slam dunk. My previous comment was just about the FTC going after false label claims and that action having no retroactive component.
The way I read it, you can make false claims with impunity UNTIL the agency comes down on you and you are forced to sign a consent order. Only after such an order will fines be levied for further violations. I see no penalty for past actions. The incentive is to make false claims and reap profits therefrom as long as possible, and stop only after you get caught.
When you come out the other side of the donut hole you are in catastrophic coverage and pay extremely small copays, more like 5% than 50%. I can testify to that. 2 vials Lantus $27!!! 2 vials Novolog about the same.